Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of Autologous Muscle Derived
Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of
tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or
radiotherapy for squamous cell cancer of the oropharynx.